Lesson plan

EQL-101

EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity. The drug is under development by Equulus Therapeutics. As of 2025, it is in the discovery or preclinical research stage of development.

Back to article

Article summary

EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity. The drug is under development by Equulus Therapeutics. As of 2025, it is in the discovery or preclinical research stage of development.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.